A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma.

Trial Profile

A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2014

At a glance

  • Drugs Fludarabine; Pixantrone; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Cell Therapeutics; CTI BioPharma
  • Most Recent Events

    • 08 Jul 2009 Additional lead trial investigator (Gorbatchevsky I) identified as reported by ClinicalTrials.gov (NCT00551239).
    • 08 Jul 2009 Additional lead trial investigator (Gorbatchevsky I) identified as reported by ClinicalTrials.gov (NCT00551239).
    • 19 Sep 2008 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top